- Home
- A Review of Emerging ARNI Data in HFrEF
A Review of Emerging ARNI Data in HFrEF
- Heart Failure
Available Credit:
- 1.00 EBAC
Course Published On:
Course Expiry Date:
Overview
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
Disclosure
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This activity has been supported by an unrestricted educational grant from Novartis.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
Target Audience
This programme is intended to educate:
- Heart Failure Specialists
- General Cardiologists
Learning Objectives
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
- understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
- interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
- apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
- Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| 1 | Welcome and Introduction | Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 2 | ARIADNE in Review | Uwe Zeymer (Klinikum Ludwigshafen, DE) | |
| 3 | Commentary on the ARIADNE Trial | Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 4 | PROVE-HF in Review | James Januzzi (Harvard Medical School, MA, US) | |
| 5 | EVALUATE-HF in Review | Akshay Desai (Harvard Medical School, MA, US) | |
| 6 | Commentary on the PROVE-HF and the EVALUATE-HF Trials | Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 7 | TRANSITION-CHF in Review | Rolf Wachter (Universität Leipzig, Leipzig, DE) | |
| 8 | PIONEER in Review | David Morrow (Harvard Medical School, MA, US) | |
| 9 | Commentary on the TRANSITION-CHF and the PIONEER Trials | Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 10 | Conclusions | Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) |
Welcome and Introduction
Duration:
Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the ARIADNE Trial
Duration:
Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the PROVE-HF and the EVALUATE-HF Trials
Duration:
Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the TRANSITION-CHF and the PIONEER Trials
Duration:
Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Conclusions
Duration:
Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Course Director
Speaker
The event ‘A Review of Emerging ARNI Data in HFrEF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
AVAILABLE CREDIT
1.00 European Board for Accreditation in Cardiology (EBAC)
Related Courses
- 1 EBAC
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1 EBAC
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1 EBAC
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
- 1 EBAC
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
Published:
Learning objectives
- Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
- Compare updates from the ACC with the 2021 ESC HF guidelines
- Recall guideline recommendations for the initiation of foundational therapy for heart failure
- Adopt foundational GMDT early in the disease course
- Postulate how ejection fraction will be used in future trials and in future guidelines
- Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
- 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
- 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
- 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
- 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points